Compare Ginkgo Bioworks Holdings Inc (DNA) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Noble Corporation plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $505.73M), while Noble Corporation plc trades at $44.25 (market cap $7.10B). The key difference: Noble Corporation plc is far larger — about 14× Ginkgo Bioworks Holdings Inc's market cap, and Noble Corporation plc pays a 4.5% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NE | |
|---|---|---|
Market Cap | $505.73M | $7.10B |
Sector | Health | Technology |
52-Week High | $16.14 | $54.37 |
52-Week Low | $5.48 | $26.61 |
Enterprise Value | $607.68M | $8.53B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Noble Corporation (NE) trades at $40.77, up 0.2% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $0.01 per share, missing estimates, while revenue declined to $3.1B in 2026 from $3.3B in 2025. Recent news includes a fraud investigation announcement and new drilling contracts, creating investor uncertainty amid operational challenges.
The outlook remains cautious with analyst consensus at Buy (31%) and a $46 price target offering 13% upside. Key risks include earnings volatility, legal scrutiny, and competitive pressures in offshore drilling. Positive cash flow and dividend payments provide some stability, but execution on new contracts and margin improvement are critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
